Related Experiment Videos
RGD-containing trypsin with both platelet aggregation inhibitory activity and proteolytic activity
1National Laboratory of Protein Engineering and Plant Genetic Engineering, College of Life Sciences, Peking University, Beijing, P.R.China.
Biochemistry and Molecular Biology International
|October 8, 1998
Summary
Researchers engineered mutant trypsins by inserting Arg-Gly-Asp (RGD) motifs to enhance integrin binding. The 77RGD mutant retained significant proteolytic activity and showed potential for therapeutic applications.
Area of Science:
- Biochemistry
- Molecular Biology
- Protein Engineering
Background:
- The Arg-Gly-Asp (RGD) motif is crucial for cell adhesion, mediating interactions between disintegrins and cell surface receptors.
- Understanding these interactions is key to developing targeted therapeutics.
Purpose of the Study:
- To engineer a mutant trypsin with high affinity for integrins while preserving proteolytic activity.
- To investigate the kinetic properties, autolytic stability, and platelet aggregation inhibitory effects of modified trypsin.
Main Methods:
- Insertion of RGDS and RGD motifs into specific regions of trypsin.
- Expression and purification of wild-type and mutant trypsins (37RGDS, 77RGD) in E. coli.
- Determination of kinetic properties, autolytic stability, and platelet aggregation inhibition.
Main Results:
- Mutant 77RGD exhibited 87% retained proteolytic activity, significantly higher than 37RGDS (34%).
- Both mutants showed decreased autolytic stability compared to wild-type trypsin.
- 37RGDS demonstrated 29% platelet aggregation inhibition, while 77RGD showed 14% inhibition at 3.5 microM concentration.
Conclusions:
- Mutant trypsin incorporating the RGD motif can exhibit altered integrin binding and proteolytic activity.
- The 77RGD mutant shows promise for applications requiring integrin-binding and enzymatic function.
- Further research is warranted to optimize these engineered proteins for therapeutic use.